Analystreport

Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "buy" rating re-affirmed by analysts at Oppenheimer Holdings Inc..

Outlook Therapeutics, Inc.  (OTLK) 
Last outlook therapeutics, inc. earnings: 2/14 08:00 am Check Earnings Report